Copy For Citation
TELLİ G., TEL B. C., Gumusel B.
Turkish Journal of Pharmaceutical Sciences, vol.17, no.3, pp.349-356, 2020 (ESCI)
-
Publication Type:
Article / Review
-
Volume:
17
Issue:
3
-
Publication Date:
2020
-
Doi Number:
10.4274/tjps.galenos.2019.47123
-
Journal Name:
Turkish Journal of Pharmaceutical Sciences
-
Journal Indexes:
Emerging Sources Citation Index (ESCI), Scopus, Academic Search Premier, EMBASE, International Pharmaceutical Abstracts, Directory of Open Access Journals, TR DİZİN (ULAKBİM)
-
Page Numbers:
pp.349-356
-
Keywords:
CGRP family, cardiopulmonary diseases, adrenomedullin, adrenomedullin2, intermedin, pulmonary hypertension, VASCULAR SMOOTH-MUSCLE, PULMONARY ARTERIAL-HYPERTENSION, ACTIVITY-MODIFYING PROTEINS, INCREASED PLASMA-LEVELS, CENTRAL-NERVOUS-SYSTEM, NITRIC-OXIDE, REGIONAL HEMODYNAMICS, SIGNAL-TRANSDUCTION, ENDOTHELIAL-CELLS, DEPENDENT PATHWAY
-
Lokman Hekim University Affiliated:
Yes
Abstract
© Turk J Pharm Sci, Published by Galenos Publishing House.Cardiopulmonary diseases are very common among the population. They are high-cost diseases and there are still no definitive treatments. The roles of members of the calcitonin-gene related-peptide (CGRP) family in treating cardiopulmonary diseases have been studied for many years and promising results obtained. Especially in recent years, two important members of the family, adrenomedullin and adrenomedullin2/intermedin, have been considered new treatment targets in cardiopulmonary diseases. In this review, the roles of CGRP family members in cardiopulmonary diseases are investigated based on the studies performed to date.